Cancer Research UK’s Commercial Partnerships team, formerly known as Cancer Research Technology (CRT), develop and commercialise exciting new discoveries in cancer research. Our deep understanding of both academia and industry enables us to translate promising research into commercial propositions for the greatest patient benefit and maximum financial return.
Exclusive rights to over £450m of cancer research in FY19/20
10 cancer drugs to market, including Rubraca, Zytiga, Lynparza, Balversa